Dr. Camille Cushman is the Principal Scientist of Viska Bio, an early-stage biotech company developing a novel antibody-enzyme fusion protein designed to activate the immune system. Camille received her B.S. in Biochemistry from Bates College before performing her graduate studies in the Division of Molecular and Cellular Oncology at Dana-Farber Cancer Institute while completing her Ph.D. in Virology from Harvard University. She has co-authored several peer-reviewed articles in top journals and has presented her work at international conferences. She brings her years of oncology research training to Viska Bio’s scientific team to advance their program targeting EGFR-high cancers.